Wiley Matthew T. 4
4 · BioXcel Therapeutics, Inc. · Filed Sep 17, 2024
Insider Transaction Report
Form 4
Wiley Matthew T.
Other
Transactions
- Sale
Common Stock
2024-09-16$0.69/sh−215$149→ 4,033 total - Exercise/Conversion
Restricted Stock Units
2024-09-15−750→ 7,500 total→ Common Stock (750 underlying) - Exercise/Conversion
Common Stock
2024-09-15+750→ 4,248 total
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
- [F3]On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.